AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11590482
Drug: VC-1500 (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC-1500 (1500 mg/day Vitamin C)
Trial: 11590482
Drug: VC-500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC-500 (500 mg/day Vitamin C)
Trial: 9533371
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg of Curosurf via dual-lumen endotracheal tube
Trial: 9533371
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg of Curosurf via bolus instillation
Trial: 2962478
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator, percutaneous coronary angioplasty, or both
Trial: 28341958
Drug: Docetaxel/cisplatin (DP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/cisplatin (DP) - docetaxel (35 mg/m2)/cisplatin (30 mg/m2) iv on days 1 and 8, every 3 weeks.
Trial: 28341958
Drug: Gemcitabine/cisplatin (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/cisplatin (GP) - gemcitabine (1000 mg/m2)/cisplatin (30 mg/m2) iv on days 1 and 8, every 3 weeks.
Trial: 22271372
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (300 mg/day)
Trial: 22271372
Drug: Amitriptyline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (10 mg/day)
Trial: 22271372
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (300 mg/day) + Amitriptyline (10 mg/day)
Trial: 21693570
Drug: DM self
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DM self management programme (experimental group) - six sessions of weekly course
Trial: 16247249
Drug: R126638 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R126638 100 mg
Trial: 16247249
Drug: R126638 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R126638 200 mg
Trial: 11115305
Drug: Glycopyrrolate (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.10 mg/kg per dose)
Trial: 1622977
Drug: Parboiled white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parboiled white rice (25 g carbohydrate)
Trial: 1622977
Drug: Parboiled white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parboiled white rice (50 g carbohydrate)
Trial: 1622977
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (25 g carbohydrate)
Trial: 1622977
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread (50 g carbohydrate)
Trial: 3924748
Drug: Omeprazole (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (0.35 mg/kg)
Trial: 10812285
Drug: THC (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (7.5 mg)
Trial: 22356757
Drug: Fallopian tube
RxNorm normalized name: SUS SCROFA FALLOPIAN TUBE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fallopian tube sperm perfusion (FSP) via Foley catheter with 4 mL of inseminate
Trial: 22356757
Drug: Standard intrauterine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intrauterine insemination (IUI) with 0.5 mL of inseminate
Trial: 18058480
Drug: diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretics
Trial: 10089853
Drug: Biventricular pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular pacing therapy
Trial: 10089853
Drug: No pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pacing therapy (control)
Trial: 10089853
Drug: Biventricular pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biventricular pacing therapy (with ICD)
Trial: 2404806
Drug: Progesterone supplementation
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone supplementation of 100 mg/day, initiated 10 hours before hCG administration and continued for 6 days.
Trial: 7370145
Drug: Meptazinol 60
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 60 mg
Trial: 19054806
Drug: Sequential Organ
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Organ Failure Assessment
Trial: 15351854
Drug: Recombinant urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant urokinase (r-UK) 5000 IU/ml
Trial: 9684393
Drug: Daily buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily buprenorphine (8 mg)
Trial: 9684393
Drug: Alternate-day dosing
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day dosing of buprenorphine and placebo
Trial: 2547138
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg piperazine oestrone sulphate
Trial: 2547138
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol
Trial: 2547138
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg oestradiol valerate
Trial: 2547138
Drug: 10.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg oestriol
Trial: 2547138
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with 250 micrograms of levonorgestrel
Trial: 2547138
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration for a week
Trial: 2547138
Drug: Regimen D
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen D (10.0 mg oestriol)
Trial: 2547138
Drug: Regimens A
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimens A (2.5 mg piperazine oestrone sulphate) and B (1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol)
Trial: 2547138
Drug: All oestrogen
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All oestrogen formulations
Trial: 2547138
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration for 7 days
Trial: 766041
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NT) treatment at high plasma levels (less than 180 ng/ml)
Trial: 766041
Drug: Evaluation after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation after 6 weeks of NT treatment
Trial: 766041
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects of NT treatment
Trial: 24815999
Drug: Overall inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall inhalation characteristics
Trial: 24815999
Drug: Overall inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall inhaled volumes
Trial: 23588939
Drug: Sulfasalazine +
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine + hydroxychloroquine (triple therapy)
Trial: 10936835
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral microscopy
Trial: 9051544
Drug: High-dose etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose etomidate (HET) 0.5 to 1.7 mg/kg titrated to an early burst suppression pattern
Trial: 9051544
Drug: Low-dose etomidate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose etomidate (LET) 0.4 to 0.6 mg/kg titrated to an EEG spectral edge frequency (SEF) of 10 to 12 Hz
Trial: 9051544
Drug: Thiopental sodium
RxNorm normalized name: Thiopental Sodium
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental sodium (THIO) 3 to 6 mg/kg titrated to the same EEG endpoint
Trial: 8119064
Drug: Long-duration adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-duration adjuvant chemotherapy
Trial: 29481630
Drug: Vinflunine 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinflunine 280 mg/m2 intravenously every 3 weeks (q3w)
Trial: 29481630
Drug: Alkylating agent
RxNorm normalized name: Alkylating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating agent (AA) monotherapy q3w
Trial: 24827034
Drug: Low-dose posaconazole
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose posaconazole (100 mg twice daily)
Trial: 24827034
Drug: High-dose posaconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose posaconazole (400 mg twice daily)
Trial: 24827034
Drug: Benznidazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benznidazole (150 mg twice daily)
Trial: 21917191
Drug: 34 g
RxNorm normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 34 g fish pâté (n 44)
Trial: 21917191
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml fruit juice (n 38)
Trial: 21917191
Drug: three capsules
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three capsules of concentrated fish oil (n 40)
Trial: 20092584
Drug: Basal-bolus regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus regimen with insulin glargine and insulin glulisine
Trial: 20092584
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin regimen
Trial: 8853248
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily plus repeated laser photocoagulation
Trial: 3006449
Drug: Captopril 75
RxNorm normalized name: captopril 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 75 mg
Trial: 1847704
Drug: Captopril with
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril with Dexamethasone (DXM) 25 mg
Trial: 1847704
Drug: Captopril with
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril with Dexamethasone (DXM) 75 mg
Trial: 6294263
Drug: Ceftriaxone 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 75 mg/kg
Trial: 6294263
Drug: Ceftriaxone 50
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 50 mg/kg
Trial: 26654212
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy for perinatal depression (MBCT-PD)
Trial: 25113509
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL of 0.33% ropivacaine and normal saline with epinephrine
Trial: 22455835
Drug: OCD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCD treatment response
Trial: 21595143
Drug: Orthopedic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopedic treatment including Minimal invasive Therapy (MIT)
Trial: 21595143
Drug: Naturopathic 'complex'-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naturopathic 'complex'-treatment
Trial: 16155268
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g resistant starch/d
Trial: 10814606
Drug: High-dose ATP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ATP infusion (75 microg.min(‐1).kg(‐1))
Trial: 10814606
Drug: Low-dose ATP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ATP infusion (37-50 microg.min(‐1).kg(‐1))
Trial: 9015906
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg o.m. plus clarithromycin 500 mg t.i.d. for 14 days (group L30)
Trial: 9015906
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group L60)
Trial: 2056290
Drug: Home air-fluidized
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home air-fluidized bed therapy
Trial: 19294953
Drug: School-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based intervention program (N = 41) consisting of four 50-minute classes over a 4-week period educating on healthy lifestyle based on cognitive-behavior therapy framework.
Trial: 11008725
Drug: 10-mg nitroglycerin
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg nitroglycerin patch
Trial: 11008725
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Control group C)
Trial: 9366699
Drug: Ofloxacin (adults,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (adults, 0.5 mL; children, 0.25 mL) twice daily for 10 days
Trial: 9366699
Drug: Cortisporin (adults,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisporin (adults, 0.2 mL; children, 0.15 mL) 4 times daily for 10 days
Trial: 1531118
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous maintenance of anaesthesia with an infusion of propofol and increments of alfentanil (Group P)
Trial: 3158128
Drug: Lidocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2 mg/min intravenous infusion following an initial bolus of 200 mg)
Trial: 31705526
Drug: Guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab 100 mg by subcutaneous injection
Trial: 26453914
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AsA) 500 mg; α-tocopherol 300 IU
Trial: 24885600
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C infusion plus oral administration of vitamin E during angioplasty, followed by oral doses of vitamins C and E for 84 days
Trial: 24885600
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C infusion plus oral administration of vitamin E
Trial: 18606481
Drug: 9vPnC‐MnCC (CRM197‐conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vPnC‐MnCC (CRM197‐conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) given in three doses (3, 4, and 5 months)
Trial: 18606481
Drug: 9vPnC‐MnCC (CRM197‐conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vPnC‐MnCC (CRM197‐conjugated pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F and meningococcal C polysaccharides) given in two doses (3 and 5 months)
Trial: 15811481
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg TID
Trial: 30484021
Drug: Wet-cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-cupping therapy
Trial: 30484021
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (rest and oral medications)
Trial: 23601029
Drug: Buccal mucosa
RxNorm normalized name: Diazepam 5 MG Buccal mucosa Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal mucosa graft urethroplasty
Trial: 21425572
Drug: Xuefu Zhuyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefu Zhuyu Capsule (Control)
Trial: 21714585
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg (group R)
Trial: 21714585
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus fenofibrate 200 mg (group RF)
Trial: 21714585
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (group RΩ)
Trial: 17402355
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group using a portable computer for daily contact with heart failure clinic
Trial: 16215713
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/day) + Metoprolol (50 mg/day)
Trial: 16215713
Drug: All drug
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drug therapy groups
Trial: 10543315
Drug: PNU-142633F 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-142633F 1.0 mg
Trial: 10543315
Drug: PNU-142633F 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-142633F 3.0 mg
Trial: 10543315
Drug: PNU-142633F 30
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-142633F 30 mg
Trial: 10543315
Drug: PNU-142633F 100
RxNorm normalized name: Trichophyton antigen 1000 PNU/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNU-142633F 100 mg
Trial: 7587604
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with glurenorm and insulin
Trial: 2339203
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (marine oil capsules)
Trial: 2339203
Drug: Aspirin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (daily dosages increasing from 162 to 2600 mg)
Trial: 6106735
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Haemophilus influenzae type b capsular polysaccharide)
Trial: 25791863
Drug: Pistachio-supplemented diet
RxNorm normalized name: Pistachio
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio-supplemented diet (PD, 57 g/d of pistachios daily)
Trial: 21098143
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zolpidem alone
Trial: 21098143
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zolpidem after 15 days of 400 mg carbamazepine
Trial: 16918657
Drug: Rocuronium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.4 mg x kg(‐1) administered i.v. before intubation (Group R, n = 59)
Trial: 15486330
Drug: Intervention (structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (structured nurse assessment, education, treatment recommendations)
Trial: 9378840
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of sinistrin
Trial: 9378840
Drug: Bolus dose
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose followed by a 6-hour infusion of sinistrin
Trial: 29446195
Drug: Brief motivational
RxNorm normalized name: ALCOHOL 300 mL in 375 mL TOPICAL LIQUID [Nelsons Clean Brier Tennessee Handwash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief motivational interviewing and cognitive-behavioural therapy
Trial: 29446195
Drug: Longer term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Longer term motivational interviewing and cognitive-behavioural therapy
Trial: 21801476
Drug: B-vitamins (5-methyl-THF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-vitamins (5-methyl-THF (560 μg); vitamin B₆ (3 mg); vitamin B₁₂ (20 μg))
Trial: 21801476
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (600 mg of EPA and DHA at a ratio of 2:1)
Trial: 21801476
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for both treatments
Trial: 20368566
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (40,000 U weekly during and after chemotherapy)
Trial: 2320062
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg, intravenous)
Trial: 2320062
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (250 mg three times a day for four weeks)
Trial: 23999198
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg and 3.0 mg
Trial: 11196760
Drug: Ferric polymaltose
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric polymaltose (6 mg/kg/d)